$9.90
0.010.15%
Last update: 10:17 AM
15 minutes delayed
Comments
Loading...
Tango Therapeutics
TNGXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Tango Therapeutics (NASDAQ:TNGX) Stock, Analyst Ratings, Price Targets, Forecasts
Tango Therapeutics Inc has a consensus price target of $16.2 based on the ratings of 11 analysts. The high is $25 issued by SVB Leerink on September 20, 2021. The low is $11 issued by Wedbush on May 23, 2024. The 3 most-recent analyst ratings were released by Jefferies, HC Wainwright & Co., and HC Wainwright & Co. on July 17, 2024, July 9, 2024, and May 28, 2024, respectively. With an average price target of $15 between Jefferies, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 51.44% upside for Tango Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
HC Wainwright & Co.
Guggenheim
Barclays
Wedbush
1calculated from analyst ratings
Analyst Ratings for Tango Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/17/2024 | Buy Now | 91.82% | Jefferies | Maury Raycroft | → $19 | Initiates | → Buy | Get Alert |
| 07/09/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt | — | Reiterates | → Overweight | Get Alert |
| 07/09/2024 | Buy Now | 31.25% | HC Wainwright & Co. | Robert Burns | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 31.25% | HC Wainwright & Co. | Robert Burns | $16 → $13 | Maintains | Buy | Get Alert |
| 05/24/2024 | Buy Now | 41.34% | Guggenheim | Charles Zhu | $16 → $14 | Maintains | Buy | Get Alert |
| 05/24/2024 | Buy Now | 31.25% | Barclays | Peter Lawson | $18 → $13 | Maintains | Overweight | Get Alert |
| 05/23/2024 | Buy Now | 11.06% | Wedbush | Robert Driscoll | $18 → $11 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | 71.63% | HC Wainwright & Co. | Robert Burns | → $17 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt | — | Initiates | → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 71.63% | HC Wainwright & Co. | Robert Burns | $16 → $17 | Maintains | Buy | Get Alert |
| 02/12/2024 | Buy Now | 81.73% | Piper Sandler | Joseph Catanzaro | → $18 | Initiates | → Overweight | Get Alert |
| 12/08/2023 | Buy Now | 61.53% | B. Riley Securities | Yuan Zhi | → $16 | Initiates | → Buy | Get Alert |
| 08/11/2023 | Buy Now | 61.53% | HC Wainwright & Co. | Robert Burns | $11 → $16 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 11.06% | HC Wainwright & Co. | Robert Burns | → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 81.73% | Wedbush | Robert Driscoll | → $18 | Reiterates | → Outperform | Get Alert |
| 03/28/2023 | Buy Now | 11.06% | HC Wainwright & Co. | Robert Burns | $10 → $11 | Maintains | Buy | Get Alert |
| 10/20/2022 | Buy Now | 0.96% | HC Wainwright & Co. | Robert Burns | → $10 | Initiates | → Buy | Get Alert |
| 09/20/2021 | Buy Now | 152.4% | SVB Leerink | Andrew Berens | — | Initiates | → Outperform | Get Alert |
| 09/07/2021 | Buy Now | 101.92% | Wedbush | Robert Driscoll | — | Initiates | → Outperform | Get Alert |
| 09/07/2021 | Buy Now | 61.53% | Guggenheim | — | — | Initiates | → Buy | Get Alert |
| 09/07/2021 | Buy Now | 71.63% | Goldman Sachs | Chris Shibutani | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Tango Therapeutics (TNGX) stock?
The latest price target for Tango Therapeutics (NASDAQ:TNGX) was reported by Jefferies on July 17, 2024. The analyst firm set a price target for $19.00 expecting TNGX to rise to within 12 months (a possible 91.82% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tango Therapeutics (TNGX)?
The latest analyst rating for Tango Therapeutics (NASDAQ:TNGX) was provided by Jefferies, and Tango Therapeutics initiated their buy rating.
When was the last upgrade for Tango Therapeutics (TNGX)?
There is no last upgrade for Tango Therapeutics
When was the last downgrade for Tango Therapeutics (TNGX)?
There is no last downgrade for Tango Therapeutics.
When is the next analyst rating going to be posted or updated for Tango Therapeutics (TNGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tango Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tango Therapeutics was filed on July 17, 2024 so you should expect the next rating to be made available sometime around July 17, 2025.
Is the Analyst Rating Tango Therapeutics (TNGX) correct?
While ratings are subjective and will change, the latest Tango Therapeutics (TNGX) rating was a initiated with a price target of $0.00 to $19.00. The current price Tango Therapeutics (TNGX) is trading at is $9.90, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.